Contents

Cardiac Remodeling..................1
Case of Two Appendixes? ..........3
Focus on Pharm.........................5

This is a new quarterly research newsletter featuring articles written by faculty of the Division of Physician Assistant Practice at Ohio University.

Cardiac Remodeling
by Jeff Vasiloff, MD, MPH

Remodeling is so important in the pathogenesis of so many diseases. What is it? First, “remodeling” is a poorly-chosen word. This is because the good-sounding word remodeling—in medicine and pathophysiology—is always maladaptive.

Pathophysiological remodeling includes “rebuilding,” but the remodeling of body tissues often only “helps” in the short term. That is, remodeling STARTS as an adaptive process, but in the long-term, this “well-intentioned” adaptation always becomes maladaptive.

Please contact Jeff Vasiloff, MD, MPH at vasiloff@ohio.edu with any questions regarding this issue. If you would like to subscribe to receive this email in the future, please contact nbell@ohio.edu.
Consider the heart. After a myocardial infarction some patients develop heart failure immediately, while a large majority do not. Due to maladaptive remodeling though, heart failure ensues in up to 25% of these patients in the next ten years.

In patients who develop heart failure within five years after a myocardial infarction, while the heart failure may not have been clinically present after the infarction, the remodeling process began with the acute infarct. In other words, the remodeling process was “set into motion” at the time of the infarction.

Thus, cardiac remodeling does not happen “for no reason”; rather, it is triggered by a pathological event or process that affects the heart. While the most common triggering pathophysiologic factor is death of myocardial tissue due to infarct, there are several other triggers that set the remodeling process in action. These include: a) ventricular pressure overload (hypertension, aortic stenosis); b) ventricular volume overload (aortic regurgitation, mitral regurgitation); c) viral myocarditis or autoimmune attack of the myocardium; d) genetic mutations of cytoskeletal and other myocardial proteins; e) alcohol and chemotherapeutic agents that damage the heart; and f) infiltration of the heart with sarcoidosis or amyloidosis or excess accumulations of iron.

When the process of remodeling takes root, there does not appear to be a homeostatic script to keep the process in check. For example, in aortic stenosis, a little bit of left ventricular hypertrophy can be initially adaptive, but progressive hypertrophy ultimately leads to impaired ventricular contraction. It is useful to think of unchecked or untreated remodeling as a runaway train headed for disaster.

This is why a goal of post-infarct therapy is to PREVENT or minimize remodeling. For example, all of the following treatment strategies act to prevent or minimize remodeling: a) blood pressure control; b) lowering of LDL cholesterol; c) adrenergic blockade with beta blockers; d) renin-angiotensin-aldosterone blockade with ACE inhibitors or angiotensin I receptor blockers (ARBs); e) coagulation system inhibition with, for example, cyclooxygenase I inhibitors (aspirin) and platelet P2Y12 inhibitors (for example, clopidogrel); f) and anti-ischemic therapy with nitrates.

While the maladaptive effects of cardiac remodeling can affect the entire heart and cardiovascular system, the underlying deleterious remodeling occurs at the molecular and cellular levels. That is, remodeling results from changes in gene expression and protein synthesis, which ultimately give rise to cellular changes such as fibrosis, hypertrophy, and necrosis.

The pathway of remodeling following an initial insult to the heart involves the secretion of sky high levels of mediators and hormones. These mediators and hormones, in turn, change the structure and function of the heart.

Some of these mediators and hormones include: a) renin; b) angiotensin I; c) angiotensin II; d) aldosterone; e) epinephrine; f) norepinephrine; g) arginine vasopressin (same as anti-diuretic hormone); h) atrial natriuretic peptide (ANP); and i) endothelin-1, among others.

It is the high levels of these mediators and hormones in both the blood and cardiac tissue that cause the maladaptive lesions and changes of remodeling.

The consequences of remodeling include such changes as: a) myocardial (or myocyte) death; b) myocyte enlargement (hypertrophy); c) deposition
of fibrous tissue; d) activation of the coagulation system; and e) chamber enlargement. These changes, in turn, can lead to: a) increased systolic (chamber) wall tension and stress; b) increased demand for oxygen; c) impaired shortening of myocardial cells during contraction; d) increased diastolic (chamber) wall tension and stress; e) decreased perfusion of the subendocardial area of the myocardium; f) impairment of “tight coupling” of myocardial depolarization and myocardial contraction; g) mitral regurgitation due to LV enlargement with separation of papillary muscles; and h) ventricular arrhythmias, including ventricular fibrillation.

Again, the many treatment modalities in patients with various heart diseases are used to attempt to prevent sequelae of maladaptive cardiac remodeling.

**Case of Two Appendixes?**

*by Shanna Raphael, PA-S and Jeff Vasiloff, MD, MPH*

**Report of a Case:**

A 25 year old women was in her usual state of health until she developed the sudden onset of severe crampy pain in the suprapubic area. This was accompanied by nausea and diarrhea without hematochezia.

She denied dysuria or frequency, and a routine gynecologic examination 3 weeks prior was unremarkable. There was no history of irritable bowel or inflammatory bowel disease. She had appendicitis 6 years ago treated with laparoscopic appendectomy.

Other past medical history was unremarkable. She is a single PA student. No history of smoking or drug use. She is a social drinker. Family history was positive for diverticulitis. Review of systems was negative except for anorexia, nausea, and abdominal pain.

Temperature was 98.3°F; pulse was 93 per minute and regular; respirations were 14 per minute; blood pressure was 147/86 mmHg; O2 saturation was 98%.

She appeared uncomfortable due to abdominal pain. HEENT exam was normal. Cardiopulmonary exam was normal. Abdomen was nondistended. There was moderate tenderness in the suprapubic
area but without peritoneal signs. There was no
CVAT and the remainder of the examination was
normal.

WBC was 11,330 mm$^3$ with 73% neutrophils, 19%
lymphs, 5% monos, and 2% basos. Hemoglobin
was 13.8 g/dL; hematocrit was 42%.

Complete metabolic panel was normal except for a
glucose of 114 mg/dL and bicarbonate of 20 meq/L.
Anion gap was 21. Lipase was normal and beta-hCG
was negative. Urinalysis revealed no white blood
cells, but 11 red blood cells per HPF. Leukocyte
esterase was negative, and bacteria were seen
only rarely.

During observation in the emergency department,
she did not have any further episodes of diarrhea,
but the abdominal pain persisted in spite of IV
analgesia. Further, she remarked that the pain
was reminiscent of her acute appendicitis 6 years
previously.

A contrast CT of the abdomen and pelvis revealed
surgical clips in the right lower quadrant,
presumably from prior appendectomy. In addition,
although the terminal ileum was not dilated, the
small bowel proximal to it was distended to 2.7cm,
consistent with low-grade partial small bowel
obstruction.

She was admitted to the surgery service where
she received IV hydration and additional pain
control. The following morning she felt some
better, but abdominal x-rays revealed some
prominent loops of small bowel with air-fluid
levels—consistent with the CT findings the day
before.

Small bowel follow through with water-soluble
contrast revealed the appearance of contrast
within the colon in 45 minutes confirming the
absence of complete obstruction.

It was decided to perform diagnostic laparoscopy,
but the patient requested postponement due to an
upcoming midterm. She was counseled on the
risks and instructed to call and return to the ED if
symptoms worsened.

Over the next week she was able to attend school
despite steady abdominal pain, which now was
most intense in the right lower quadrant. She also
had constipation. Her oral intake was reduced
because of occasional nausea and vomiting.

Nine days after discharge she was readmitted for
diagnostic laparoscopy. Preoperatively, her
abdomen was nondistended, but diffuse
tenderness to palpation was present. There were
no peritoneal signs and WBC was 7,730 mm$^3$.

Full diagnostic laparoscopy of the abdomen and
pelvis revealed a normal appearing small bowel at
its surface. Then it was run—“hand over hand”—
laparoscopically with the robot. The bowel in the
right lower quadrant was saved for last.

Inspection of the right lower quadrant revealed the
cecum to be rotated into the colic gutter. Also,
there were staples along the peritoneum overlying
the iliac vessels—secondary to prior
appendectomy.

In addition, the area was bound down by dense
adhesions, which were lysed. This allowed the
straightening out of the cecum and terminal ileum.
It could then be seen that there was a 15–20 cm
fecalized segment of small bowel leading to the
ileocecal valve and cecum. There was also the
presence of an unknown structure that contained
staple lines.

Further dissection revealed that the unknown
structure was appendix. That is, about half of the
appendix was found remaining. Thus, in the
appendectomy 6 years previously, only part of the
appendix had been removed.

The rest of the appendix—down to its attachment
to cecum—was resected. The remnant was
removed through the port site.
Examination of the specimen revealed a large remnant of the appendix, which, surprisingly, did not appear inflamed. The appendiceal remnant, however, was missing the tip, which is consistent with prior partial resection, leaving behind most of the body of the appendix. Resection of the remnant appendix and adhesions relieved the constriction of the distal ileum.

Discussion:

Bowel obstruction refers to the blockage of transit through the lumen of the bowel. Blockage or obstruction can be complete or partial. Common causes of bowel obstruction include physical or mechanical blockage or “functional” blockage, the latter usually due to bowel hypomotility—that is, paralytic ileus.

The leading cause of mechanical obstruction of the small bowel is a “pinching” or constriction of the bowel lumen due to entrapment by fibrous adhesions from previous surgeries or inflammatory conditions. Entrapment within hernias (inguinal, incisional, ventral, for example) is the second leading cause.

Less common causes include: a) intussusception (telescoping of one segment of bowel within another); b) volvulus (twisting constriction of the bowel); and c) intraluminal blockages, such as caused by a small bowel tumor or impacted gallstone (gallstone ileus);

Appendectomy is one of the most common surgical procedures. Postoperative complications include wound infection, bleeding, intrabdominal abscess, small bowel obstruction, and stump appendicitis.

Most cases of small bowel obstruction following appendectomy are caused by adhesions. The formation of these fibrous bands is to be expected following intraperitoneal surgery or secondary to inflammation. On some occasions, these bands form orifices or “passageways” into which small bowel can enter and become entrapped.

This is what appears to have happened in this case, with the additional feature of the presence of a remnant of the appendix also bound down with adhesions.

Leaving an appendiceal remnant (also called a “stump”) has been reported to be associated with bowel obstruction. In 2004, Gordon et. al. reported a 36 year old woman who developed partial small bowel obstruction 10 days after laparoscopic appendectomy. At operation, there was no stump appendicitis, but, rather, the tip of the stump was affixed to the mesentery of the terminal ileum, which lead to the entrapment of the terminal ileum.

More common than bowel obstruction in the presence of a remnant appendix, is acute inflammation of the remnant—so called “stump appendicitis.”

In 2011, Roberts et. al. reviewed all reported cases of stump appendicitis. There were 48 cases, including 3 of their own patients. Stump appendicitis presents like acute appendicitis, but, of course, in a patient who has already undergone (“partial”) appendectomy.

Thus, it is important that PA’s remember that in a patient presenting with acute right lower quadrant pain and a history of prior appendectomy, stump appendicitis or even stump-related small bowel obstruction are diagnostic possibilities.

References:


From 2000 to 2018, Ohio has seen a 14% increase in obese adults.\(^1\) Currently, Ohio ranks number 17 in the United States for adult obesity.\(^1\) It is well known that obesity is a risk factor for type 2 diabetes, cardiovascular disease, and hypertension. Addressing weight is a necessary part of improving overall health for patients. Implementing a healthy diet and increasing physical activity are essential to long-term weight management. Some patients may benefit from the addition of weight loss drugs to jump-start the process or help them stay on track with lifestyle changes. There are both controlled and non-controlled medications FDA approved for weight loss. Unique rules in Ohio address the prescribing of controlled substances for weight loss. While these rules may be cause for pause, understanding them gives the provider an added tool when helping patients lose weight.

Although there are four FDA approved medications for short-term management of weight reduction, phentermine (Adipex-P\(^5\), Lomaira\(^5\)) is the most commonly prescribed.\(^3,4\) To prescribe this drug in Ohio, the prescriber must be a physician. The physician must first review the patient’s medical record and assess what attempts have been made to lose weight.\(^5\) If past attempts have been unsuccessful and the physician is considering prescribing phentermine, several steps must take place. The physician begins by completing a history and physical, calculating the patient’s BMI, and assessing contraindications to the use of phentermine.\(^5\) The patient’s BMI must be 30 or higher (27 or higher with comorbidities) to initiate treatment.\(^5\) If there are no contraindications and the BMI requirement is met, the physician may prescribe phentermine in conjunction with diet and exercise.

Prescriptions for phentermine may not exceed 30 days and total treatment time may not exceed 12 weeks.\(^5\) The physician must see the patient in person at least every 30 days during treatment with phentermine to assess progress.\(^5\) At the completion of 12 weeks of treatment, the patient may not start another short-term weight loss medication for 6 months.\(^5\) However, where appropriate, the physician may switch the patient to one of the long-term controlled substances for weight loss.

Qsymia\(^5\) (phentermine/topiramate) and Belviq\(^5\) (lorcaserin) are FDA approved controlled substances for the long-term management of weight loss.\(^6,7\) Beginning treatment with these medications also begins with an in-person visit with the physician who will complete a history and physical, calculate the patient’s BMI, and assess contraindications to the use of either medication.\(^8\) The physician will see the patient, face-to-face, every 30 days for two additional follow-up visits.\(^8\) After the first three visits, the physician can choose to write a six month prescription for the patient and/or have the patient followed by their physician assistant.\(^8\) Physician assistants may not change the prescribed medication to a different product.\(^8\)

As with any controlled substance in Ohio, OARRS must be monitored.\(^5,8\) Patients with a history of
drug abuse or those who have provided false information regarding controlled substance use should not receive controlled substances for weight loss. Signs of abuse or diversion while taking controlled substances for weight loss should be investigated and discontinuation of therapy may be warranted.

References:


3. LOMAIRA. https://lomaira.com/?gclid=EAIaIQobChMI0K3wvu_V5AIVycDACH03cwAXEAAYASAAEgKpM_D_BwE. Accessed September 16, 2019.


